Obstetrics and GynecologyObstetrics and GynecologyАкушерство и гинекология0300-90922412-5679Bionika Media247370ArticlesСтатьиReview ArticleOPTIMIZATION OF MENOPAUSAL HORMONE THERAPY-RELATED RISKS: MONOTHERAPY WITH TRANSDERMAL ESTROGENS OR IN COMBINATION WITH MICRONIZED PROGESTERONE. ADVANTAGES AGAINST VENOUS THROMBOEMBOLISM AND BREAST CANCERОптимизация рисков МГТ: монотерапия трансдермальными эстрогенами или в комбинации с микронизированным прогестероном. Преимущества в отношении венозной тромбоэмболии и рака молочной железыYurenevaSvetlana VladimirovnaЮреневаСветлана Владимировна

MD

д.м.н., отделение гинекологической эндокринологии

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of RussiaФГБУ Научный центр акушерства, гинекологии и перинатологии им. академика В.И. Кулакова Минздрава России150520155NO5 (2015)№5 (2015)192518022023Copyright ©; 2015, Bionika MediaCopyright ©; 2015, ООО «Бионика Медиа»2015Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/0300-9092/article/view/247370

После опубликования результатов исследования «Инициатива во имя здоровья женщин» (WHI) приоритетное значение приобрели вопросы не только эффективности, но и безопасности менопаузальной гормональной терапии (МГТ). Согласно временной гипотезе МГТ безопасна у здоровых женщин в течение 5-7 лет, если она начата до возраста 60 лет и/или в течение 10 лет постменопаузы, когда многие женщин нуждаются в таком лечении. Второй ключевой вопрос - это правильный выбор лечения, принимая во внимание широкий спектр препаратов для МГТ, в том числе парентеральных, имеющийся в арсенале современного врача. Цель исследования. Рассмотреть возможные пути снижения наиболее важных рисков МГТ, такие как венозная тромбоэмболия и рак молочной железы, при использовании монотерапии трансдермальными эстрогенами или в комбинации с микронизированным прогестероном. Материал и методы. Проведен обзор опубликованных после 2002 г. клинических и экспериментальных исследований надлежащего качества, касающихся безопасности МГТ с фокусом на трансдермальный эстрадиол и микронизированный прогестерон. Результаты. Польза и риски МГТ значительно отличаются в зависимости от многих факторов, в том числе от выбора пути введения гормонов. Данные наблюдательных исследований свидетельствуют о более низком риске венозной тромбоэмболии и рака молочной железы при применении трансдермальных эстрогенов у женщин после гистерэктомии или в комбинации с микронизированным прогестероном у женщин с интактной маткой. Заключение. Необходимо проведение рандомизированных контролируемых исследований для подтверждения нейтрального влияния трансдермального эстрадиола и перорального микронизированного прогестерона на главные риски МГТ.

менопаузальная гормональная терапиятрансдермальные эстрогенымикронизированный прогестеронвенозная тромбоэмболиярак молочной железыэстрожельутрожестанDe Villiers T.J., Gass M.L.S., Haines C.J., Hall J.E., Lobo R.A., Pierroz D.D., Rees M. Global consensus statement on menopausal hormone therapy. Climacteric. 2013; 16(2): 203-4.De Villiers T.J., Pines A., Panay N., Gambacciani M., Archer D.F., Baber R.J. et al.; International Menopause Society. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2013; 16(3): 316-37.Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002; 288(3): 321-33.Anderson G.L., Limacher M., Assaf A.R., Bassford T., Beresford S.A., Black H. et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004; 291(14): 1701-12.Hodis H.N., Mack W.J. The timing hypothesis and hormone replacement therapy: a paradigm shift in the primary prevention of coronary heart disease in women. 1. Comparison of therapeutic efficacy. J. Am. Geriatr. Soc. 2013; 61(6): 1005-10.Manson J.E., Chlebowski R.T., Stefanick M.L., Aragaki A.K., Rossouw J.E., Prentice R.L. et al. Menopausal hormone therapy and health outcomes during the intervention and extended post stopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013; 310(13): 1353-68.Harman S.M., Black D.M., Naftolin F., Brinton E.A., Budojf M.J., Cedars M.I. et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann. Intern. Med. 2014; 161(4): 249-60.Hodis H.N. ELITE - Does the trial outcome confirm or refute the timing hypothesis of hormone therapy? In: Presented at the14th World Congress on Menopause of the International Menopause Society. May 1-4, 2014, Cancun, Mexico.Smith N.L., Blondon M., Wiggins K.L., Harrington L.B., van Hylckama Vlieg A., Floyd J.S. et al. Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. JAMA Intern. Med. 2014; 174(1): 25-31.Stanczyk F.Z., Hapgood J.P., Winer S., Mishell D.R. Jr. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr. Rev. 2013; 34(2): 171-208.Sitruk-Ware R., El-Etr M. Progesterone and related progestins: potential new health benefits. Climacteric. 2013; 16(Suppl.1): 69-78.Modena M.G., Sismondi P., Mueck A.O., Kuttenn F., Lignières Bd., Verhaeghe J. et al. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas. 2005; 52(1): 1-10.Liu B. Is transdermal menopausal hormone therapy a safer option than oral therapy? Can. Med. Assoc. J. 2013; 185(7): 549-50.Corbelli J., Shaikh N., Wessel C., Hess R. Low-dose transdermal estradiol for vasomotor symptoms: a systematic review. Menopause. 2015; 22(1): 114-21.Langer R.D. Efficacy, safety, and tolerability of low-dose hormone therapy in managing menopausal symptoms. J. Am. Board. Fam. Med. 2009; 22(5): 563-73.Allen N.E., Tsilidis K.K., Key T.J., Dossus L., Kaaks R., Lund E. et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition. Am. J. Epidemiol. 2010; 172(12): 1394-403.L’Hermite M. HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT. Climacteric. 2013; 16(Suppl.1): 44-53.Rossouw J.E., Manson J.E., Kaunitz A.M., Anderson G.L. Lessons learned from the Women’s Health Initiative trials of menopausal hormone therapy. Obstet. Gynecol. 2013; 121(1): 172-6.Cohen A.T., Agnelli G., Anderson F.A., Arcelus J.I., Bergqvist D., Brecht J.G. et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb. Haemost. 2007; 98(4): 756-64.Morange P.E., Trégouët D.A. Current knowledge on the genetics of incident venous thrombosis. J. Thromb. Haemost. 2013; 11(Suppl.1): 111-21.Scarabin P.Y. Hormone therapy and venous thromboembolism among postmenopausal women. Front. Horm. Res. 2014; 43: 21-32.Mosca L., Benjamin E.J., Berra K., Bezanson J.L., Dolor R.J., Lloyd-Jones D.M. et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. Circulation. 2011; 123(11): 1243-62.American College of Obstetricians and Gynecologists. ACOG committee opinion no. 556. Postmenopausal estrogen therapy: route of administration and risk of venous Thromboembolism. Obstet. Gynecol. 2013; 121(4): 887-90.Post M.S., Christella M., Thomassen L.G., van der Mooren M.J., van Baal W.M., Rosing J. et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler. Thromb. Vasc. Biol. 2003; 23(6): 1116-21.Oger E., Alhenc-Gelas M., Lacut K., Blouch M.T., Roudaut N., Kerlan V. et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. SARAH Investigators. Arterioscler. Thromb. Vasc. Biol. 2003; 23(9): 1671-6.Eilertsen A.L., H0ibraaten E., Os I., Andersen T.O., Sandvik L., Sandset P.M. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis. Maturitas. 2005; 52(2): 111-8.Folsom A.R., Lutsey P.L., Astor B.C., Cushman M. C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort. Thromb. Haemost. 2009; 102(4): 615-9.Scarabin P.Y., Alhenc-Gelas M., Plu-Bureau G., Taisne P., Agher R., Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler. Thromb. Vasc. Biol. 1997; 17(11): 3071-8.Canonico M., Oger E., Plu-Bureau G., Conard J., Meyer G., Lévesque H. et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007; 115(7): 840-5.Canonico M., Fournier A., Carcaillon L., Olié V., Plu-Bureau G., Oger E. et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism results from the E3N cohort study. Arterioscler. Thromb. Vasc. Biol. 2010; 30(2): 340-5.Renoux C., Dell’Aniello S., Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: population-based study. J. Thromb. Haemost. 2010; 8(5): 979-86.Sweetland S., Beral V., Balkwill A., Liu B., Benson V.S., Canonico M. et al.; The Million Women Study Collaborators. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J. Thromb. Haemost. 2012; 10(11): 2277-86.Roach R.E., Lijfering W.M., Helmerhorst F.M., Cannegieter S.C., Rosendaal F.R., van Hylckama Vlieg A. The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy. J. Thromb. Haemost. 2013; 11(1): 124-31.Vickers M.R., MacLennan A.H., Lawton B. et al. Main morbidities recorded in the Women’s International Study of Long Duration Oestrogen after Menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. Br. Med. J. 2007; 335: 239.Herkert O., Kuhl H., Sandow J., Busse R., Schini-Kerth V.B. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor. Circulation. 2001; 104(23): 2826-31.Gompel A., Santen R.J. Hormone therapy and breast cancer risk 10 years after the WHI. Climacteric. 2012; 15(3): 241-9.Kim J.J., Kurita T., Bulun S.E. Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr. Rev. 2013; 34(1): 130-62.Kuhl H., Schneider H.P.G. Progesterone - promoter or inhibitor of breast cancer. Climacteric. 2013; 16(Suppl.1): 54-68.Fournier A., Berrino F., Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res. Treat. 2008; 107(1): 103-11.Lyytinen H., Pukkala E., Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet. Gynecol. 2009; 113(1): 65-73.Fournier A., Fabre A., Mesrine S., Boutron-Ruault M.C., Berrino F., Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J. Clin. Oncol. 2008; 26(8): 1260- 8.Wood C.E., Register T.C., Lees C.J., Chen H., Kimrey S., Cline J.M. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res. Treat. 2007; 101(2): 125-34.Wood C.E., Register T.C., Cline J.M. Transcriptional profiles of progestogen effects in the postmenopausal breast. Breast Cancer Res. Treat. 2009; 114(2): 233-42.Courtin A., Communal L., Vilasco M., Cimino D., Mourra N. de Bortoli M. et al. Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells. Breast Cancer Res. Treat. 2012; 131(1): 49-63.Murkes D., Conner P., Leifland K., Tani E., Beliard A., Lundström E., Söderqvist G. Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women. Fertil. Steril. 2011; 95(3): 1188-91.Murkes D., Lalitkumar P.G., Leifland K., Lundström E., Söderqvist G. Percutaneous estradiol/oral micronized progesterone has less-adverse effects and different gene regulations than oral conjugated equine estrogens/ medroxyprogesterone acetate in the breasts of healthy women in vivo. Gynecol. Endocrinol. 2012; 28(Suppl.2): 12-5.Simon J.A. What if the Women’s Health Initiative had used transdermal estradiol and oral progesterone instead? Menopause. 2014; 21(7): 769-83.